DNA Modifiers: A Novel Therapeutic Strategy for Targeting Known DDR-Deficient GBMs

Time: 4:30 pm
day: Conference Day Two


  • Design and discovery of novel covalent DNA modifying agents (DNA Modifiers) that exploit existing glioma DDR defects such as MGMT and overcome common clinical resistance mechanisms.
  • KL-50: the first DNA Modifier to generate a dynamic bifunctional DNA modification that exploits differences in repair kinetics to generate time- and MGMT-dependent DNA interstrand crosslinks
  • Proof of principle of KL-50 efficacy and tolerability across numerous GBM cell lines, invivo, and in PDX models with expansion of platform to other DDR biomarkers